Adam Rosenberg, RyCarma Therapeutics CEO
January 7, 2025 05:30 AM EST
People
Startups

Ex­clu­sive: For­bion-backed car­dio biotech re­brands to RyCar­ma with Phase 2 plans

Kyle LaHucik

Senior Reporter

A 20-year-old biotech work­ing on small mol­e­cule treat­ments for car­dio­vas­cu­lar and skele­tal mus­cle dis­eases has re­brand­ed and plans to en­ter Phase 2 in heart fail­ure …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

A service from the Financial Times